5 hours ago
Lululemon Athletica Inc. (NASDAQ:LULU) recently issued its second guidance cut of the year, and investors responded immediately by sending shares down roughly 18%. That selloff came despite an EPS beat, but the headline result was heavily supported by a tariff refund rather than underlying business strength. Brand sentiment, traffic, and leggings sales are all weakening across the company's two largest markets. The key issue for investors is no longer whether the quarter was weak, but whether the stock's low valuation and new CEO can provide the catalyst for a meaningful recovery.
Lululemon shares dropped 18% after the company lowered its full-year guidance for the second time this year. Revenue is now projected to range from $10.35 billion to $10.5 billion, while EPS guidance was reduced to $9.48 to $9.73. Both represent sharp reductions from its earlier guidance ranges. Second-quarter revenue was particularly weak, falling 4% to $2.4 billion and coming in below consensus estimates, while comparable sales dropped 9%, or 10% on a constant-dollar basis. According to the company, negative commentary had affected traffic in both the U.S. and China, while leggings sales slowed more than expected. Although reported EPS beat estimates, nearly all of that upside came from an $0.86 per share tariff refund. For the third quarter, management expects revenue to decline another 10% to 11%.
Lululemon still has several financial advantages that could support the business through its current slowdown. The company has no outstanding borrowings and maintains $1.4 billion in cash. First-half operating cash flow climbed to $589 million, more than double the prior year. Inventory per unit also declined roughly 7% year over year, reducing the risk of a margin-damaging clearance event. Meanwhile, shares have fallen over 50% year-to-date and now trade at a historically depressed valuation, potentially creating an out-of-favor-setup for investors. At the same time, management continued its buyback program, repurchasing $330 million worth of shares during the quarter.
The weakness in traffic and leggings sales cannot be ignored, and both remain serious concerns. However, the company has a debt-free balance sheet, stronger cash generation, and a valuation that already reflects much of the recent bad news. That gives Lululemon room to prove that its current struggles are mainly execution-related rather than signs of a structural decline.
#year #shares #company
Lululemon shares dropped 18% after the company lowered its full-year guidance for the second time this year. Revenue is now projected to range from $10.35 billion to $10.5 billion, while EPS guidance was reduced to $9.48 to $9.73. Both represent sharp reductions from its earlier guidance ranges. Second-quarter revenue was particularly weak, falling 4% to $2.4 billion and coming in below consensus estimates, while comparable sales dropped 9%, or 10% on a constant-dollar basis. According to the company, negative commentary had affected traffic in both the U.S. and China, while leggings sales slowed more than expected. Although reported EPS beat estimates, nearly all of that upside came from an $0.86 per share tariff refund. For the third quarter, management expects revenue to decline another 10% to 11%.
Lululemon still has several financial advantages that could support the business through its current slowdown. The company has no outstanding borrowings and maintains $1.4 billion in cash. First-half operating cash flow climbed to $589 million, more than double the prior year. Inventory per unit also declined roughly 7% year over year, reducing the risk of a margin-damaging clearance event. Meanwhile, shares have fallen over 50% year-to-date and now trade at a historically depressed valuation, potentially creating an out-of-favor-setup for investors. At the same time, management continued its buyback program, repurchasing $330 million worth of shares during the quarter.
The weakness in traffic and leggings sales cannot be ignored, and both remain serious concerns. However, the company has a debt-free balance sheet, stronger cash generation, and a valuation that already reflects much of the recent bad news. That gives Lululemon room to prove that its current struggles are mainly execution-related rather than signs of a structural decline.
#year #shares #company
5 hours ago
Toward the end of the lightning round on September 8, when a caller inquired about AstraZeneca PLC (NYSE:AZN), Mad Money host Jim Cramer commented:
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
Alright, now, AstraZeneca reminds me of a company, it's not unlike Novartis. I'm a little nervous about it. It's been missing some of its trials. I don't think COPD is enough to change my mind… I am not going to put my money on AstraZeneca.
AstraZeneca PLC (NYSE:AZN) maintains a solid financial foundation supported by steady top-line growth and disciplined cost management. In its second-quarter report, the company generated total revenue of $15.38 billion, marking a 6.4% increase compared to the same period last year. Adjusted earnings per share reached $2.63, outperforming ****** yst consensus estimates.
The profitability was driven by strong global demand for core oncology and rare disease treatments, which successfully offset revenue headwinds from generic competition affecting older blockbusters like Farxiga and Brilinta. With a net margin hovering around 17.02% and management reiterating its full-year guidance for mid-to-high single-digit revenue growth along with low double-digit core EPS expansion, the core business continues to demonstrate commercial resilience.
The primary driver behind the skepticism could be based on tangible execution risks and regulatory hurdles that threaten AstraZeneca PLC's (NYSE:AZN) long-term top line. A significant blow to the rare disease division came when anselamimab failed to achieve statistical significance for the primary endpoint in the overall AL amyloidosis population in the Phase III CARES program, although AstraZeneca reported encouraging results in a prespecified subgroup of patients with kappa light-chain amyloidosis.
#management
6 hours ago
Nike stock has fallen 40% year to date to $37, raising the question of whether it's dead money or set for a category-driven bounce.
On Holding is down 41% and Lululemon down 53% year to date, signaling a category-wide selloff rather than a Nike-specific execution failure.
With SPY up 12% and XLY down just 5%, athletic apparel's 40-53% collapse stands out as a sector being systematically repriced.
Just released. Our ****** ysts combed the entire stock market and named the ten best stocks to buy right now, and Nike didn't make the cut. Enter your email to see the names that beat NKE. The report is free. Enter your email and see if any of your stocks made the cut.
Shares of Nike (NYSE:NKE) are up 0.96% in Friday afternoon and trading at $36.97, a small bid that barely dents a brutal year. Nike stock is down 40% year to date (YTD), and today's uptick doesn't answer the bigger question hanging over the name.
#nike #question #category #stocks
On Holding is down 41% and Lululemon down 53% year to date, signaling a category-wide selloff rather than a Nike-specific execution failure.
With SPY up 12% and XLY down just 5%, athletic apparel's 40-53% collapse stands out as a sector being systematically repriced.
Just released. Our ****** ysts combed the entire stock market and named the ten best stocks to buy right now, and Nike didn't make the cut. Enter your email to see the names that beat NKE. The report is free. Enter your email and see if any of your stocks made the cut.
Shares of Nike (NYSE:NKE) are up 0.96% in Friday afternoon and trading at $36.97, a small bid that barely dents a brutal year. Nike stock is down 40% year to date (YTD), and today's uptick doesn't answer the bigger question hanging over the name.
#nike #question #category #stocks
6 hours ago
On September 8, a caller inquired if Trinity Industries, Inc. (NYSE:TRN) is worth looking at after its recent pullback. Mad Money host Jim Cramer replied:
Yes, Railcar, shouldn't be down this much. I like your thinking. You waited for the big hit. Now, it's in a good place. I would pull the trigger.
Trinity Industries, Inc. (NYSE:TRN) has faced a sharp correction, pulling back significantly from its 52-week high of $38.31. Despite this downward pressure, the company's fundamental **** et base remains exceptionally stable. In its second-quarter earnings report, the company posted total revenues of $485 million and diluted earnings per share from continuing operations of $1.25, with earnings benefiting from a $132 million non-cash pre-tax gain tied to the Napier Park railcar partnership transaction.
The leasing and services segment continues to support the business, posting a robust fleet utilization rate of 97.3% and an improved lease renewal success rate of 75%. In addition, the Future Lease Rate Differential improved to +3.5%, showing healthy pricing power on expiring contracts. Management reaffirmed its full-year EPS guidance of $2.20 to $2.40, supported by a solid railcar backlog standing at $1.6 billion.
The primary catalyst for Trinity Industries, Inc.'s (NYSE:TRN) recent sell-off stems from margin compression within the Rail Products manufacturing division. Operating margins in manufacturing faced pressure from an unplanned production interruption at the Longview manufacturing facility and temporary realignment expenses tied to the company's Mexican footprint. These localized execution issues overshadowed a strong quarterly performance in leasing, causing the stock to drift below both its 50-day and 200-day moving average.
#trinity
Yes, Railcar, shouldn't be down this much. I like your thinking. You waited for the big hit. Now, it's in a good place. I would pull the trigger.
Trinity Industries, Inc. (NYSE:TRN) has faced a sharp correction, pulling back significantly from its 52-week high of $38.31. Despite this downward pressure, the company's fundamental **** et base remains exceptionally stable. In its second-quarter earnings report, the company posted total revenues of $485 million and diluted earnings per share from continuing operations of $1.25, with earnings benefiting from a $132 million non-cash pre-tax gain tied to the Napier Park railcar partnership transaction.
The leasing and services segment continues to support the business, posting a robust fleet utilization rate of 97.3% and an improved lease renewal success rate of 75%. In addition, the Future Lease Rate Differential improved to +3.5%, showing healthy pricing power on expiring contracts. Management reaffirmed its full-year EPS guidance of $2.20 to $2.40, supported by a solid railcar backlog standing at $1.6 billion.
The primary catalyst for Trinity Industries, Inc.'s (NYSE:TRN) recent sell-off stems from margin compression within the Rail Products manufacturing division. Operating margins in manufacturing faced pressure from an unplanned production interruption at the Longview manufacturing facility and temporary realignment expenses tied to the company's Mexican footprint. These localized execution issues overshadowed a strong quarterly performance in leasing, causing the stock to drift below both its 50-day and 200-day moving average.
#trinity
8 hours ago
On September 10, Piper Sandler **** yst Bill Carcache initiated coverage of Q2 Holdings, Inc. (NYSE:QTWO), giving the stock an Overweight rating and setting the price target at $82.
The research firm started coverage on companies in the payments and consumer finance group and named Q2 Holdings, Inc. (NYSE:QTWO) as its preferred name in the sector.
According to Piper Sandler, the company offers the "clearest combination" of subscription revenue growth, visibility into annual recurring revenue, and improving free cash flow conversion. The firm also highlighted the company's growing margins and debt-free balance sheet. Piper Sandler said these factors support what it sees as the clearest path toward durable growth among the payments and consumer finance group.
Q2 Holdings, Inc. (NYSE:QTWO) delivered strong financial performance in Q2 2026. The company reported revenue of $219.8 million, an increase of 13% year-over-year and 2% sequentially. GAAP gross margin improved to 59.2% from 53.6% in the prior-year quarter, while GAAP net income rose to $29.9 million from $11.8 million.
Adjusted EBITDA reached a record $62.8 million, up 37% year-over-year. The company said it delivered another quarter of consistent execution, with strong bookings across its solutions.
#year #NYSE #revenue
The research firm started coverage on companies in the payments and consumer finance group and named Q2 Holdings, Inc. (NYSE:QTWO) as its preferred name in the sector.
According to Piper Sandler, the company offers the "clearest combination" of subscription revenue growth, visibility into annual recurring revenue, and improving free cash flow conversion. The firm also highlighted the company's growing margins and debt-free balance sheet. Piper Sandler said these factors support what it sees as the clearest path toward durable growth among the payments and consumer finance group.
Q2 Holdings, Inc. (NYSE:QTWO) delivered strong financial performance in Q2 2026. The company reported revenue of $219.8 million, an increase of 13% year-over-year and 2% sequentially. GAAP gross margin improved to 59.2% from 53.6% in the prior-year quarter, while GAAP net income rose to $29.9 million from $11.8 million.
Adjusted EBITDA reached a record $62.8 million, up 37% year-over-year. The company said it delivered another quarter of consistent execution, with strong bookings across its solutions.
#year #NYSE #revenue
9 hours ago
New England Patriots coach Mike Vrabel doesn't have any regrets about his decision to rest the starters during the three-game preseason slate.
However, it was clear that the team showed rust in Wednesday's 13-10 loss to the Seattle Seahawks, particularly on the offensive side of the ball. Vrabel opted to use the preseason to focus on the roster depth and preserve the health of the starters.
That's a decision that he continued to defend after the disappointing loss in the season opener.
"Playing the backups for the Eagles or the Colts for eight plays, I don't think was going to prepare us for what we saw last night," Vrabel told media members. "I thought we handled the environment; I thought we did. I know the execution wasn't good enough, but the line of scrimmage, penalties, the operation, those things gave us a chance. Some other things didn't give us a chance."
Mike Vrabel on if he regrets not playing any Patriots starters in the preseason.
"Playing the backups of the Eagles or Colts for eight plays I don't think was going to prepare us for what we saw last night." pic.twitter.com/L1efdmrmsk
#starters #colts #regrets
However, it was clear that the team showed rust in Wednesday's 13-10 loss to the Seattle Seahawks, particularly on the offensive side of the ball. Vrabel opted to use the preseason to focus on the roster depth and preserve the health of the starters.
That's a decision that he continued to defend after the disappointing loss in the season opener.
"Playing the backups for the Eagles or the Colts for eight plays, I don't think was going to prepare us for what we saw last night," Vrabel told media members. "I thought we handled the environment; I thought we did. I know the execution wasn't good enough, but the line of scrimmage, penalties, the operation, those things gave us a chance. Some other things didn't give us a chance."
Mike Vrabel on if he regrets not playing any Patriots starters in the preseason.
"Playing the backups of the Eagles or Colts for eight plays I don't think was going to prepare us for what we saw last night." pic.twitter.com/L1efdmrmsk
#starters #colts #regrets
18 hours ago
We've got a game that counts on our hands Sunday afternoon, when the Commanders play the Eagles in Philadelphia.
In a word: Finally.
The 2026 NFL regular season is here, where we finally see what all those free-agent signings, NFL draft picks new play callers can do for a Commanders team looking to rebound from a 5-12 showing.
Starting the season against host Philadelphia is no easy task. It will require quality and consistent execution from both sides of the football, winning tough matchups and finding a way to pull through at the end.
We could pick darn near anyone as a key player in this matchup, but we'll stick to five Commanders (not named Jayden Daniels) to watch heading into this NFC East clash:
#Eagles #starting
In a word: Finally.
The 2026 NFL regular season is here, where we finally see what all those free-agent signings, NFL draft picks new play callers can do for a Commanders team looking to rebound from a 5-12 showing.
Starting the season against host Philadelphia is no easy task. It will require quality and consistent execution from both sides of the football, winning tough matchups and finding a way to pull through at the end.
We could pick darn near anyone as a key player in this matchup, but we'll stick to five Commanders (not named Jayden Daniels) to watch heading into this NFC East clash:
#Eagles #starting
1 day ago
Washington Commanders head coach Dan Quinn is beloved by his players. Whether it was during his time as a position coach, defensive coordinator, or now in his second tenure as an NFL head coach, Quinn is loved and respected across the NFL.
There's a reason why you hear other prominent players on rival teams express their love and respect for Quinn, such as Micah Parsons. Most recently, Quinn has taken a special interest in Washington's first-round pick, linebacker Sonny Styles. During training camp, Quinn referenced a conversation he had with Styles about making mistakes.
"We're chasing hard to have absolute elite execution," Quinn said last month. "I also recognize there are gonna be mistakes, and I want them to happen when you're working right on the edge of something; you're going to make them. I encouraged Sonny just the other day: make them. I want you to test yourself to see: Can I go to that ****** e to get the ball? Can I be in that location? Can I go take my shot? I want them right on the edge, knowing that mistakes are part of it, and then when they happen, that they don't get repeated. And so, that's the execution piece."
Great advice from Quinn to a talented young player adjusting to life in the NFL who may be afraid of making mistakes.
Styles recently shared some notable advice that Quinn gave him.
#want #making
There's a reason why you hear other prominent players on rival teams express their love and respect for Quinn, such as Micah Parsons. Most recently, Quinn has taken a special interest in Washington's first-round pick, linebacker Sonny Styles. During training camp, Quinn referenced a conversation he had with Styles about making mistakes.
"We're chasing hard to have absolute elite execution," Quinn said last month. "I also recognize there are gonna be mistakes, and I want them to happen when you're working right on the edge of something; you're going to make them. I encouraged Sonny just the other day: make them. I want you to test yourself to see: Can I go to that ****** e to get the ball? Can I be in that location? Can I go take my shot? I want them right on the edge, knowing that mistakes are part of it, and then when they happen, that they don't get repeated. And so, that's the execution piece."
Great advice from Quinn to a talented young player adjusting to life in the NFL who may be afraid of making mistakes.
Styles recently shared some notable advice that Quinn gave him.
#want #making
1 day ago
Northern Trust Corporation (NASDAQ:NTRS) announced on September 7 that Warwickshire Pension Fund had appointed it to provide global custody, valuation reporting, capital call execution and performance measurement. The UK public pension fund has approximately £3.6 billion, or $4.8 billion, in ****** ets.
The appointment strengthens the pension-servicing franchise of Northern Trust Corporation (NASDAQ:NTRS). Contract duration and fees were not disclosed in the announcement. The investment question is whether the relationship can generate meaningful recurring revenue and support further wins.
Scale sets the hurdle. Northern Trust Corporation (NASDAQ:NTRS) reported $20.0 trillion of ****** ets under custody or administration at June 30. Warwickshire's ****** ets equal approximately 0.024% of that base. The pension ****** ets represent a servicing opportunity, with revenue depending on the services provided and contractual pricing.
Northern Trust Corporation (NASDAQ:NTRS) won responsibility for several connected functions. Combining custody, valuation reporting, and performance measurement could make the relationship more embedded in the fund's operations. Capital call execution also provides a role in supporting private-market investments.
Warwickshire is one of 18 partner funds in Border to Coast Pensions Partnership. For Northern Trust Corporation (NASDAQ:NTRS), successful delivery could provide a reference for additional pension mandates. The opportunity lies in repeating the service model across clients and expanding relationships as operational needs evolve.
#pension #assets
The appointment strengthens the pension-servicing franchise of Northern Trust Corporation (NASDAQ:NTRS). Contract duration and fees were not disclosed in the announcement. The investment question is whether the relationship can generate meaningful recurring revenue and support further wins.
Scale sets the hurdle. Northern Trust Corporation (NASDAQ:NTRS) reported $20.0 trillion of ****** ets under custody or administration at June 30. Warwickshire's ****** ets equal approximately 0.024% of that base. The pension ****** ets represent a servicing opportunity, with revenue depending on the services provided and contractual pricing.
Northern Trust Corporation (NASDAQ:NTRS) won responsibility for several connected functions. Combining custody, valuation reporting, and performance measurement could make the relationship more embedded in the fund's operations. Capital call execution also provides a role in supporting private-market investments.
Warwickshire is one of 18 partner funds in Border to Coast Pensions Partnership. For Northern Trust Corporation (NASDAQ:NTRS), successful delivery could provide a reference for additional pension mandates. The opportunity lies in repeating the service model across clients and expanding relationships as operational needs evolve.
#pension #assets
1 day ago
A Brazilian federal judge ordered the immediate suspension of all environmental licenses held by Sigma Mineração S.A., the operating subsidiary of Sigma Lithium Corporation (NASDAQ:SGML), for the Grota do Cirilo project. The September 4 preliminary order also halted mining activities following a civil action brought by the Federation of Quilombola Communities of Minas Gerais.
The dispute centers on whether the project lies within the area of influence of the Baú Quilombola Community and therefore required free, prior, and informed consultation. The judge cited studies placing the community's territory approximately 2.7 kilometers from the project's directly affected area, within the 8-kilometer presumptive regulatory impact radius applicable to mining projects outside Brazil's Legal Amazon under Interministerial Ordinance No. 60/2015. Sigma Lithium Corporation (NASDAQ:SGML) has argued that the project is outside the relevant impact zone.
The court ordered independent georeferencing and barred Minas Gerais and its environmental agency from issuing new licenses, amendments, or corrective approvals until the community-protection requirements are completed.
Two routes remain. If independent georeferencing supports the boundary position, Sigma Lithium Corporation (NASDAQ:SGML) could seek favorable court relief modifying or reversing the suspension. This provides an alternative to completing the consultation requirements.
If the project falls within the regulated impact area, Sigma Lithium Corporation (NASDAQ:SGML) would need Incra approval of the Quilombola Component Study, Basic Quilombola Environmental Plan and Final Execution Report, plus free, prior and informed consultation with the Baú community. Completing those requirements could preserve the project if acceptable mitigation is agreed.
#corporation #sgml #project #community
The dispute centers on whether the project lies within the area of influence of the Baú Quilombola Community and therefore required free, prior, and informed consultation. The judge cited studies placing the community's territory approximately 2.7 kilometers from the project's directly affected area, within the 8-kilometer presumptive regulatory impact radius applicable to mining projects outside Brazil's Legal Amazon under Interministerial Ordinance No. 60/2015. Sigma Lithium Corporation (NASDAQ:SGML) has argued that the project is outside the relevant impact zone.
The court ordered independent georeferencing and barred Minas Gerais and its environmental agency from issuing new licenses, amendments, or corrective approvals until the community-protection requirements are completed.
Two routes remain. If independent georeferencing supports the boundary position, Sigma Lithium Corporation (NASDAQ:SGML) could seek favorable court relief modifying or reversing the suspension. This provides an alternative to completing the consultation requirements.
If the project falls within the regulated impact area, Sigma Lithium Corporation (NASDAQ:SGML) would need Incra approval of the Quilombola Component Study, Basic Quilombola Environmental Plan and Final Execution Report, plus free, prior and informed consultation with the Baú community. Completing those requirements could preserve the project if acceptable mitigation is agreed.
#corporation #sgml #project #community
1 day ago
WASHINGTON, Sept 11 (Reuters) - The contractor responsible for renovating the Lincoln Memorial Reflecting Pool in Washington told U.S. President Donald Trump's administration that errors in its work and flaws in the repair plan caused the pool's liner to peel and break loose, the New York Times reported on Friday, citing documents it reviewed.
Trump has repeatedly blamed problems with the newly renovated pool, including its new blue paint peeling off, on vandalism.
According to the New York Times, citing the documents, Atlantic Industrial Coatings found problems in the design and execution of the renovation.
Workers did not spray enough primer in some areas, the contractor said in the cited documents, and layers of the liner included incompatible chemicals. The bottom layer blistered and loosened as the chemical on top reached a hotter temperature than the one underneath could withstand, the New York Times said.
The documents include the contractor's reports to the government and daily progress updates from the National Park Service over the past two months, the New York Times said.
#sept
Trump has repeatedly blamed problems with the newly renovated pool, including its new blue paint peeling off, on vandalism.
According to the New York Times, citing the documents, Atlantic Industrial Coatings found problems in the design and execution of the renovation.
Workers did not spray enough primer in some areas, the contractor said in the cited documents, and layers of the liner included incompatible chemicals. The bottom layer blistered and loosened as the chemical on top reached a hotter temperature than the one underneath could withstand, the New York Times said.
The documents include the contractor's reports to the government and daily progress updates from the National Park Service over the past two months, the New York Times said.
#sept
2 days ago
On September 2, Shell Offshore, a subsidiary of Shell plc (NYSE:SHEL), announced the acquisition of a 30% working interest in Conifer, an exploration prospect operated by BP p.l.c. (NYSE:BP) in the U.S. Gulf of Mexico. Located offshore within Keathley Canyon near BP's Kaskida host development, Conifer represents a significant deep-water play. BP retains operatorship, with the initial exploration well expected to spud in 2027. While the deal reflects shared risk and capital efficiency in high-cost offshore basins, comparing the two giants' Q2 2026 earnings shows that Shell is currently executing from a position of superior financial strength.
Shell plc (NYSE:SHEL) delivered an exceptionally clean Q2 2026 report. Adjusted earnings reached $9.8 billion, driven by record upstream production in Brazil and record refinery utilization, which offset Middle East operational outages. Cash flow from operations (CFFO) came in at $21.4 billion, supported by higher realized prices and a $3.4 billion working capital inflow. Shell maintained strict capital discipline, reiterating its full-year capex outlook of $24 billion–$26 billion while completing $5.8 billion in structural cost reductions since 2022. Balance sheet health remains robust, with gearing at 19% and net debt at $42 billion ($12 billion excluding leases).
BP p.l.c. (NYSE:BP) also turned in a solid Q2 recovery, but its headline metrics lag behind Shell's scale. BP reported underlying replacement cost profit (its proxy for net income) of $5.7 billion, a 78% quarter-over-quarter rebound fueled by strong refining margins and oil trading. Operating cash flow reached $10.9 billion after absorbing a $1.0 billion working capital build. BP used strong cash generation to trim net debt down to $22.25 billion, while guiding full-year capex to $13.5 billion–$14.0 billion.
Although BP raised its quarterly dividend by 4% to 8.66 cents, Shell's cash engine allowed it to announce its 19th consecutive quarter of at least $3 billion in share buybacks, distributing 44% of CFFO over the trailing 12 months.
Shell's bull case centers on superior capital allocation, aggressive portfolio high-grading, including the ARC Resources acquisition targeting a 4% production CAGR through 2030, and consistent share buybacks. The bear case focuses on execution risks in integrated gas and LNG amid volatile market conditions, as well as the challenges of integrating large-scale acquisitions.
#cost
Shell plc (NYSE:SHEL) delivered an exceptionally clean Q2 2026 report. Adjusted earnings reached $9.8 billion, driven by record upstream production in Brazil and record refinery utilization, which offset Middle East operational outages. Cash flow from operations (CFFO) came in at $21.4 billion, supported by higher realized prices and a $3.4 billion working capital inflow. Shell maintained strict capital discipline, reiterating its full-year capex outlook of $24 billion–$26 billion while completing $5.8 billion in structural cost reductions since 2022. Balance sheet health remains robust, with gearing at 19% and net debt at $42 billion ($12 billion excluding leases).
BP p.l.c. (NYSE:BP) also turned in a solid Q2 recovery, but its headline metrics lag behind Shell's scale. BP reported underlying replacement cost profit (its proxy for net income) of $5.7 billion, a 78% quarter-over-quarter rebound fueled by strong refining margins and oil trading. Operating cash flow reached $10.9 billion after absorbing a $1.0 billion working capital build. BP used strong cash generation to trim net debt down to $22.25 billion, while guiding full-year capex to $13.5 billion–$14.0 billion.
Although BP raised its quarterly dividend by 4% to 8.66 cents, Shell's cash engine allowed it to announce its 19th consecutive quarter of at least $3 billion in share buybacks, distributing 44% of CFFO over the trailing 12 months.
Shell's bull case centers on superior capital allocation, aggressive portfolio high-grading, including the ARC Resources acquisition targeting a 4% production CAGR through 2030, and consistent share buybacks. The bear case focuses on execution risks in integrated gas and LNG amid volatile market conditions, as well as the challenges of integrating large-scale acquisitions.
#cost
2 days ago
Hewlett Packard Enterprise Company (NYSE:HPE) announced an expanded collaboration with Oracle Corporation (NYSE:ORCL) on September 2 to scale Oracle's global AI infrastructure using HPE Juniper Networking across Oracle Cloud Infrastructure (OCI) data centers. The partnership builds on over a decade of joint engineering, leveraging HPE's routing and switching platforms to support OCI's expanding gigawatt-scale GPU superclusters. To align long-term incentives, HPE issued stock warrants to Oracle.
Following the announcement, Wall Street delivered fast price target hikes: Barclays' Tim Long raised HPE's target by $12 to $79 (Overweight), citing server upside and robust margins, while Morgan Stanley's Sanjit Singh boosted Oracle's target by $3 to $210 (Equal Weight), noting a tactically positive setup driven by GPUaaS demand.
Hewlett Packard Enterprise Company (NYSE:HPE) and Oracle both delivered strong results, although Oracle operates at a significantly larger scale. HPE reported record Q3 2026 revenue of $12.2 billion, up 34% year over year, driven by strong server demand and a 74.9% increase in Networking revenue to $2.9 billion. GAAP diluted EPS reached $1.06, while strong execution led management to raise full-year FY26 revenue growth guidance to 34%-37% and its free cash flow target to at least $3.75 billion.
Oracle Corporation (NYSE:ORCL), meanwhile, ended fiscal 2026 with record Q4 revenue of $19.2 billion, up 21% year over year, and full-year revenue of $67.4 billion, up 17%. Q4 Cloud Infrastructure (IaaS) revenue surged 93% to $5.8 billion, while full-year GAAP EPS rose 34% to $5.83 and Remaining Performance Obligations (RPO) jumped 363% to $638 billion.
Overall, ORCL leads in hyper-growth and long-term backlog, reinforcing its position as the stronger software and cloud play, while HPE is demonstrating stronger near-term hardware momentum and attractive cash flow generation for value-oriented investors.
#billion #revenue #infrastructure
Following the announcement, Wall Street delivered fast price target hikes: Barclays' Tim Long raised HPE's target by $12 to $79 (Overweight), citing server upside and robust margins, while Morgan Stanley's Sanjit Singh boosted Oracle's target by $3 to $210 (Equal Weight), noting a tactically positive setup driven by GPUaaS demand.
Hewlett Packard Enterprise Company (NYSE:HPE) and Oracle both delivered strong results, although Oracle operates at a significantly larger scale. HPE reported record Q3 2026 revenue of $12.2 billion, up 34% year over year, driven by strong server demand and a 74.9% increase in Networking revenue to $2.9 billion. GAAP diluted EPS reached $1.06, while strong execution led management to raise full-year FY26 revenue growth guidance to 34%-37% and its free cash flow target to at least $3.75 billion.
Oracle Corporation (NYSE:ORCL), meanwhile, ended fiscal 2026 with record Q4 revenue of $19.2 billion, up 21% year over year, and full-year revenue of $67.4 billion, up 17%. Q4 Cloud Infrastructure (IaaS) revenue surged 93% to $5.8 billion, while full-year GAAP EPS rose 34% to $5.83 and Remaining Performance Obligations (RPO) jumped 363% to $638 billion.
Overall, ORCL leads in hyper-growth and long-term backlog, reinforcing its position as the stronger software and cloud play, while HPE is demonstrating stronger near-term hardware momentum and attractive cash flow generation for value-oriented investors.
#billion #revenue #infrastructure
2 days ago
On September 3, a caller asked if UnitedHealth Group Incorporated (NYSE:UNH) has enough profitable growth that they should consider adding it to their portfolio. Mad Money host Jim Cramer replied:
Yes, the answer: it does, it does. You know, I've got to tell you, I thought that last quarter was very, very good. The stock market did not like the quarter as much as I thought it would, but the stock's making a stand here. I think that UNH is good to buy.
Cramer's bullish stance rests on the core strength of the company's financial delivery and improving execution. In its second-quarter 2026 report, UnitedHealth Group Incorporated (NYSE:UNH) posted consolidated revenues of $112 billion and operating earnings of $8 billion. Adjusted diluted earnings per share reached $6.38, outpacing Wall Street expectations by $1.48. Driven by strong performance across both the UnitedHealthcare and Optum divisions, management raised its full-year 2026 adjusted EPS guidance to a range of $19.50 to $20. Furthermore, the medical care ratio improved to 86.7% down from 89.4% a year prior, showing that medical cost trends and pricing are aligning effectively.
On the other hand, Wall Street remains cautious about lingering cost pressures across the managed care landscape. Even though the medical care ratio improved compared to last year, patients continuing to utilize medical services at a high rate keeps expenses heavy. At the same time, commercial insurance margins are taking longer to bounce back. Adding in tighter payment adjustments for government-backed plans along with heavy spending on tech infrastructure, cautious investors could have reasons to wait rather than chasing the stock higher.
Insider Monkey's data tracking over 1000 hedge funds shows accumulation by major ****** et managers. 143 hedge funds had positions in UnitedHealth Group Incorporated (NYSE:UNH) in Q2 compared to 130 in Q1. Of those funds, Fisher ****** et Management was the top shareholder with nearly 9.1 million shares. The firm increased its position in the stock by 74% in the quarter. Additionally, short interest remains low, with the short percentage of the float sitting at 1.92%, showing a general lack of aggressive bearish bets against the stock.
#unitedhealth #funds
Yes, the answer: it does, it does. You know, I've got to tell you, I thought that last quarter was very, very good. The stock market did not like the quarter as much as I thought it would, but the stock's making a stand here. I think that UNH is good to buy.
Cramer's bullish stance rests on the core strength of the company's financial delivery and improving execution. In its second-quarter 2026 report, UnitedHealth Group Incorporated (NYSE:UNH) posted consolidated revenues of $112 billion and operating earnings of $8 billion. Adjusted diluted earnings per share reached $6.38, outpacing Wall Street expectations by $1.48. Driven by strong performance across both the UnitedHealthcare and Optum divisions, management raised its full-year 2026 adjusted EPS guidance to a range of $19.50 to $20. Furthermore, the medical care ratio improved to 86.7% down from 89.4% a year prior, showing that medical cost trends and pricing are aligning effectively.
On the other hand, Wall Street remains cautious about lingering cost pressures across the managed care landscape. Even though the medical care ratio improved compared to last year, patients continuing to utilize medical services at a high rate keeps expenses heavy. At the same time, commercial insurance margins are taking longer to bounce back. Adding in tighter payment adjustments for government-backed plans along with heavy spending on tech infrastructure, cautious investors could have reasons to wait rather than chasing the stock higher.
Insider Monkey's data tracking over 1000 hedge funds shows accumulation by major ****** et managers. 143 hedge funds had positions in UnitedHealth Group Incorporated (NYSE:UNH) in Q2 compared to 130 in Q1. Of those funds, Fisher ****** et Management was the top shareholder with nearly 9.1 million shares. The firm increased its position in the stock by 74% in the quarter. Additionally, short interest remains low, with the short percentage of the float sitting at 1.92%, showing a general lack of aggressive bearish bets against the stock.
#unitedhealth #funds
2 days ago
Interested in Qualcomm Incorporated? Here are five stocks we like better.
Qualcomm's Amazon agreement gives its data center strategy a major anchor beyond smartphones.
Amazon's warrants are tied to up to $60 billion in potential purchases over a decade, making the deal meaningful but gradual.
Qualcomm's valuation still trails many AI infrastructure peers, but dilution risk and execution timing remain important factors.
Investors continue to seek disciplined strategies to participate in the evolving artificial intelligence (AI) economy without paying inflated multiples for standard graphics hardware. Capital remains focused on businesses positioned to sustain steady enterprise workload expansion while maintaining reasonable valuation metrics.
#interested #qualcomm
Qualcomm's Amazon agreement gives its data center strategy a major anchor beyond smartphones.
Amazon's warrants are tied to up to $60 billion in potential purchases over a decade, making the deal meaningful but gradual.
Qualcomm's valuation still trails many AI infrastructure peers, but dilution risk and execution timing remain important factors.
Investors continue to seek disciplined strategies to participate in the evolving artificial intelligence (AI) economy without paying inflated multiples for standard graphics hardware. Capital remains focused on businesses positioned to sustain steady enterprise workload expansion while maintaining reasonable valuation metrics.
#interested #qualcomm
2 days ago
Wall Street has bid up defense contractors on geopolitical tensions alongside expanded missile-defense funding, but Northrop Grumman Corporation (NYSE:NOC) remains an outlier. On September 4, 2026, the company secured a $508.5 million Missile Defense Agency contract for ICBM and IRBM target flight-test support running through 2035. The non-competitive contract follows the $3 billion (approx.) in framework agreements to expand solid-rocket-motor production for PAC-3 and THAAD interceptors. Despite these bookings, stock slipped 2.5% to $515. The stock is trading near 16 times earnings and 33% below its peak, making Northrop one of the lowest-multiple prime defense contractors.
Northrop is one of the largest-cap defense contractors with exposure to Golden Dome through ******* e sensors and interceptors, while the Sentinel ICBM and the B-21 bomber provide additional exposure to broader U.S. strategic modernization. The recent bookings back that up: the $508.5 million MDA award, the ~$3 billion PAC-3 and THAAD agreements that will double and triple solid-rocket-motor capacity, and $1.4 billion of IBCS-related U.S. and Polish air-and-missile-defense awards announced in 2025. The latest MDA contract includes cost-plus, cost-reimbursable, and fixed-price-incentive elements, which reduce some financial exposure compared with purely fixed-price development work. Long-term missile-shield funding, however, remains tied to both political and defense bets. Legislative approval introduces timing risk, but the bull thesis is already working.
Execution problems explain the valuation discount. The Sentinel ICBM program triggered a critical Nunn-McCurdy breach after projected costs rose 81% to roughly $141 billion, forcing a Pentagon program restructuring. Concurrently, low-rate initial production on the B-21 bomber generated approximately $2 billion in pre-tax charges on fixed-price commitments. Management must demonstrate that these losses have ceased. Till then, multiple expansion will remain limited. Lockheed trades at roughly 19 times earnings compared with Northrop at about 16 times.
Institutional positioning does not point to aggressiveness in short trades. Our Insider Monkey database tracked 59 hedge funds holding NOC in the second quarter of 2026, compared to 62 in the first quarter. Short interest sits at 1.7% of the float, representing a low number of bets against the stock. Paired with -0.11 beta and a 1.9% dividend yield, the stock offers portfolio diversification at a discounted entry multiple.
#northrop
Northrop is one of the largest-cap defense contractors with exposure to Golden Dome through ******* e sensors and interceptors, while the Sentinel ICBM and the B-21 bomber provide additional exposure to broader U.S. strategic modernization. The recent bookings back that up: the $508.5 million MDA award, the ~$3 billion PAC-3 and THAAD agreements that will double and triple solid-rocket-motor capacity, and $1.4 billion of IBCS-related U.S. and Polish air-and-missile-defense awards announced in 2025. The latest MDA contract includes cost-plus, cost-reimbursable, and fixed-price-incentive elements, which reduce some financial exposure compared with purely fixed-price development work. Long-term missile-shield funding, however, remains tied to both political and defense bets. Legislative approval introduces timing risk, but the bull thesis is already working.
Execution problems explain the valuation discount. The Sentinel ICBM program triggered a critical Nunn-McCurdy breach after projected costs rose 81% to roughly $141 billion, forcing a Pentagon program restructuring. Concurrently, low-rate initial production on the B-21 bomber generated approximately $2 billion in pre-tax charges on fixed-price commitments. Management must demonstrate that these losses have ceased. Till then, multiple expansion will remain limited. Lockheed trades at roughly 19 times earnings compared with Northrop at about 16 times.
Institutional positioning does not point to aggressiveness in short trades. Our Insider Monkey database tracked 59 hedge funds holding NOC in the second quarter of 2026, compared to 62 in the first quarter. Short interest sits at 1.7% of the float, representing a low number of bets against the stock. Paired with -0.11 beta and a 1.9% dividend yield, the stock offers portfolio diversification at a discounted entry multiple.
#northrop
2 days ago
By Karen Roman
Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025.
Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of the biopharmaceutical development process, the company stated.
"As we advance our proprietary BiTAC technology platform and growing oncology pipeline, Raju's expertise will be highly valuable in optimizing our capital strategy, evaluating strategic opportunities and supporting disciplined execution and long-term shareholder value creation," said Christoph Antz, Ph.D., VERAXA's CEO and co-founder.
Contact:
#willener #roman #NASDAQ
Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025.
Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of the biopharmaceutical development process, the company stated.
"As we advance our proprietary BiTAC technology platform and growing oncology pipeline, Raju's expertise will be highly valuable in optimizing our capital strategy, evaluating strategic opportunities and supporting disciplined execution and long-term shareholder value creation," said Christoph Antz, Ph.D., VERAXA's CEO and co-founder.
Contact:
#willener #roman #NASDAQ
2 days ago
The Los Angeles Rams lost five games last season by a total of 17 points. In their first game of 2026, they were blown out by the San Francisco 49ers, 27-7.
It was an embarrassing showing for the Super Bowl favorites, getting absolutely steamrolled by Kyle Shanahan and the 49ers in Australia. Was it jet lag? A lack of preparation? Just some poor execution? No matter the reason, the Rams couldn't have started the year in worse fashion.
Given the high expectations, fans and ***** ysts naturally had plenty of jokes. The Rams got trolled relentlessly on social media, drawing criticism for sleeping through their season opener. Here's how the NFL world reacted to their shocking loss in Melbourne.
This article originally appeared on Rams Wire: NFL world roasts Rams for getting blown out by 49ers in Week 1
#World #francisco #kyle
It was an embarrassing showing for the Super Bowl favorites, getting absolutely steamrolled by Kyle Shanahan and the 49ers in Australia. Was it jet lag? A lack of preparation? Just some poor execution? No matter the reason, the Rams couldn't have started the year in worse fashion.
Given the high expectations, fans and ***** ysts naturally had plenty of jokes. The Rams got trolled relentlessly on social media, drawing criticism for sleeping through their season opener. Here's how the NFL world reacted to their shocking loss in Melbourne.
This article originally appeared on Rams Wire: NFL world roasts Rams for getting blown out by 49ers in Week 1
#World #francisco #kyle
2 days ago
ZETA combines data, AI, automation, and execution into a single platform to turn data into strategic decisions with measurable outcomes – and its initial marketing focus is broadening. The company's second-quarter 2026 report showed $443 million in revenue (a 44% year-over-year gain), adjusted EBITDA of $92 million (a 56% jump), net income of $8.2 million or $0.03 per share (after a loss of nearly $13 million the prior quarter), and offered full-year EPS guidance of $0.11.
It's no wonder ZETA shares are up 51% this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.
Institutional volumes reveal plenty. In the last year, ZETA has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in ZETA shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of technology names are under accumulation right now. But there's a powerful fundamental story happening with Zeta Global.
#million #data #institutional #quarter
It's no wonder ZETA shares are up 51% this year – and they could rise more. MoneyFlows data shows how Big Money investors are once again betting heavily on the forward picture of the stock.
Institutional volumes reveal plenty. In the last year, ZETA has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in ZETA shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of technology names are under accumulation right now. But there's a powerful fundamental story happening with Zeta Global.
#million #data #institutional #quarter
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
3 days ago
This story was originally published on C-Store Dive. To receive daily news and insights, subscribe to our free daily C-Store Dive newsletter.
Pilot has promoted Jamie Landis to executive vice president and chief administrative officer, a spokesperson for the travel center chain confirmed to C-Store Dive.
Landis, who was named senior vice president of business planning and execution in 2024, will continue leading that function while **** uming leadership of Pilot's safety, enterprise risk, procurement and communications functions. She will also spearhead the company's people team.
Landis succeeds Julius **** , who announced his resignation via social media last week. **** said in a LinkedIn post that he will remain at Pilot through the end of the year as an executive advisor to the CEO. Pilot's website reflects both leadership changes.
Landis' updated company bio says she is responsible for developing, refining and helping execute Pilot's long-term strategy, and for advancing the company's business ambition and supporting more than 30,000 team members across North America.
#landis #daily #vice
Pilot has promoted Jamie Landis to executive vice president and chief administrative officer, a spokesperson for the travel center chain confirmed to C-Store Dive.
Landis, who was named senior vice president of business planning and execution in 2024, will continue leading that function while **** uming leadership of Pilot's safety, enterprise risk, procurement and communications functions. She will also spearhead the company's people team.
Landis succeeds Julius **** , who announced his resignation via social media last week. **** said in a LinkedIn post that he will remain at Pilot through the end of the year as an executive advisor to the CEO. Pilot's website reflects both leadership changes.
Landis' updated company bio says she is responsible for developing, refining and helping execute Pilot's long-term strategy, and for advancing the company's business ambition and supporting more than 30,000 team members across North America.
#landis #daily #vice
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
5 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Performance was driven by the disciplined execution of a value creation strategy, resulting in 27% full-year adjusted EBITDA growth despite reported sales declines from network optimization.
Management attributes underlying sales growth to the $90 billion target addressable market of differentiated retailers, who increased their grocery industry share by 30 basis points.
Operational efficiency improved through the deployment of 'Lean' daily management to 44 distribution centers, resulting in four consecutive quarters of fill rate and throughput gains.
The natural product segment continues to outperform the broader market, reflecting enduring consumer demand for health-forward and specialty products.
#resulting #performance #ebitda #operational
Performance was driven by the disciplined execution of a value creation strategy, resulting in 27% full-year adjusted EBITDA growth despite reported sales declines from network optimization.
Management attributes underlying sales growth to the $90 billion target addressable market of differentiated retailers, who increased their grocery industry share by 30 basis points.
Operational efficiency improved through the deployment of 'Lean' daily management to 44 distribution centers, resulting in four consecutive quarters of fill rate and throughput gains.
The natural product segment continues to outperform the broader market, reflecting enduring consumer demand for health-forward and specialty products.
#resulting #performance #ebitda #operational
5 days ago
Stewart ***** et Management's flagship portfolio returned 15.97%, net of fees, in the second quarter, and the S&P 500 Index gained 15.20%. YTD, it appreciated 5.37%, net of fees, and the S&P 500 Index gained 10.21%. The letter can be downloaded here. Despite geopolitical uncertainties, share prices surged higher as emerging prospects for a ceasefire in the Middle East restored market composure and investor optimism for continued earnings growth in the second half of the year. Volatility in share prices was noted, particularly tied to industrial trends like AI, with comparisons made to the internet boom and personal computer adoption. Despite concerns about extreme valuations and potential corrections, the conclusion is that strong earnings growth is fundamental to rising share prices, emphasizing the importance of investing in robust businesses. Please check the fund's top five holdings for its best picks in 2026.
In its second-quarter 2026 investor letter, Stewart ***** et Management highlighted Lumentum Holdings Inc. (NASDAQ:LITE). Lumentum Holdings Inc. (NASDAQ:LITE) is a leading technology company that manufactures and sells optical and photonic products. On September 04, 2026, Lumentum Holdings Inc. (NASDAQ:LITE) closed at $881.26 per share. Over the past month, Lumentum Holdings Inc. (NASDAQ:LITE) gained 13.83%, and its shares are up 519.81% over the past year. Lumentum Holdings Inc. (NASDAQ:LITE) has a market capitalization of $79.05 billion, and its stock has traded within a 52-week range of $144.52 to $1,085.68.
Stewart ***** et Management stated the following regarding Lumentum Holdings Inc. (NASDAQ:LITE) in its Q2 2026 investor letter:
"During the quarter we initiated a small investment in Lumentum Holdings Inc. (NASDAQ:LITE), a leader in optical networking — the hardware that moves data between AI chips, servers, and data centers. We believe AI infrastructure spending is driving an optical upgrade cycle from which Lumentum may benefit. Demand outstrips supply, and customer agreements now extend through 2027 as data centers grow in number and size. Capturing this opportunity requires execution on capacity expansion and continued hyperscaler willingness to invest in AI infrastructure. The primary risks ***** ociated with the company are its concentration of revenue from a small number of customers, product timelines shifting and emerging technologies. However, we believe that the positives noted above outweigh these risks."
Lumentum Holdings Inc. (NASDAQ:LITE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 111 hedge fund portfolios held Lumentum Holdings Inc. (NASDAQ:LITE) at the end of the second quarter, down from 123 in the previous quarter. While we acknowledge the potential of Lumentum Holdings Inc. (NASDAQ:LITE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that a
In its second-quarter 2026 investor letter, Stewart ***** et Management highlighted Lumentum Holdings Inc. (NASDAQ:LITE). Lumentum Holdings Inc. (NASDAQ:LITE) is a leading technology company that manufactures and sells optical and photonic products. On September 04, 2026, Lumentum Holdings Inc. (NASDAQ:LITE) closed at $881.26 per share. Over the past month, Lumentum Holdings Inc. (NASDAQ:LITE) gained 13.83%, and its shares are up 519.81% over the past year. Lumentum Holdings Inc. (NASDAQ:LITE) has a market capitalization of $79.05 billion, and its stock has traded within a 52-week range of $144.52 to $1,085.68.
Stewart ***** et Management stated the following regarding Lumentum Holdings Inc. (NASDAQ:LITE) in its Q2 2026 investor letter:
"During the quarter we initiated a small investment in Lumentum Holdings Inc. (NASDAQ:LITE), a leader in optical networking — the hardware that moves data between AI chips, servers, and data centers. We believe AI infrastructure spending is driving an optical upgrade cycle from which Lumentum may benefit. Demand outstrips supply, and customer agreements now extend through 2027 as data centers grow in number and size. Capturing this opportunity requires execution on capacity expansion and continued hyperscaler willingness to invest in AI infrastructure. The primary risks ***** ociated with the company are its concentration of revenue from a small number of customers, product timelines shifting and emerging technologies. However, we believe that the positives noted above outweigh these risks."
Lumentum Holdings Inc. (NASDAQ:LITE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 111 hedge fund portfolios held Lumentum Holdings Inc. (NASDAQ:LITE) at the end of the second quarter, down from 123 in the previous quarter. While we acknowledge the potential of Lumentum Holdings Inc. (NASDAQ:LITE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that a
5 days ago
The decision will see the planned closure of Cone Denim's Jiaxing facility in Zhejiang province, marking a major step in its ongoing strategic transformation.
Cone Denim says the withdrawal follows a "comprehensive review" of its manufacturing footprint, the global denim market and changes in customer sourcing needs.
Recent changes in global trade, evolving customer strategies, cost pressures, supply chain considerations and broader geopolitical circumstances all contributed to the determination to curtail denim production in China.
Cone Denim president Steve Maggard explained: "We are positioning Cone Denim for its next chapter of success, with a clear priority to continue delivering for our customers with the quality, innovation, reliability, and service that have defined Cone Denim for generations.
"Closing the China facility was a difficult but necessary decision as we position Cone Denim for long-term competitiveness in a changing global market. While this marks a significant change in our manufacturing network, our commitment to serving customers remains unchanged, and we are committed to supporting our customers, employees, suppliers, and local stakeholders through this transition with transparency, care, and disciplined execution."
#global #changes
Cone Denim says the withdrawal follows a "comprehensive review" of its manufacturing footprint, the global denim market and changes in customer sourcing needs.
Recent changes in global trade, evolving customer strategies, cost pressures, supply chain considerations and broader geopolitical circumstances all contributed to the determination to curtail denim production in China.
Cone Denim president Steve Maggard explained: "We are positioning Cone Denim for its next chapter of success, with a clear priority to continue delivering for our customers with the quality, innovation, reliability, and service that have defined Cone Denim for generations.
"Closing the China facility was a difficult but necessary decision as we position Cone Denim for long-term competitiveness in a changing global market. While this marks a significant change in our manufacturing network, our commitment to serving customers remains unchanged, and we are committed to supporting our customers, employees, suppliers, and local stakeholders through this transition with transparency, care, and disciplined execution."
#global #changes
5 days ago
Lucid Group, Inc. (NASDAQ:LCID) is recalling 27,185 of its Air luxury sedans in the U.S. because an exterior lighting circuit could overheat and raise the risk of fire, the National Highway Traffic Safety Administration said on August 28.
NHTSA told owners to park outside and away from structures until a fix is deployed and warned the overheating circuit could also knock out exterior lighting, raising crash risk too. Lucid already released a free over-the-air software update, and NHTSA said 20,719 of the affected vehicles had received it before the announcement.
The recall is Lucid's largest ever, covering more cars than it delivered in all of 2025, when it handed over 15,841 vehicles. It follows a May recall of 2,039 vehicles over lost drive power and a January recall of more than 10,000 vehicles over rearview camera problems.
Lucid Group, Inc. (NASDAQ:LCID)'s top line continues to grow despite its operational challenges, as second-quarter revenue jumped 56% year over year to about $405 million and 44% sequentially. The growth was helped by higher deliveries, a better product mix, a 3.7% increase in average selling price, and $25 million in additional regulatory credit sales. This growth gives Lucid a stronger revenue base as management works to improve the firm's basic economics.
New CEO Silvio Napoli has also introduced a specific turnaround plan with measurable targets. His operational reset plans to generate $1.4 billion in cash-flow improvements this year. It directly addresses problems such as premature product launches, inadequate service investment, and slow responses to quality issues. A more disciplined approach could help Lucid reduce execution problems and rebuild investor confidence.
#lucid #recall #problems #group
NHTSA told owners to park outside and away from structures until a fix is deployed and warned the overheating circuit could also knock out exterior lighting, raising crash risk too. Lucid already released a free over-the-air software update, and NHTSA said 20,719 of the affected vehicles had received it before the announcement.
The recall is Lucid's largest ever, covering more cars than it delivered in all of 2025, when it handed over 15,841 vehicles. It follows a May recall of 2,039 vehicles over lost drive power and a January recall of more than 10,000 vehicles over rearview camera problems.
Lucid Group, Inc. (NASDAQ:LCID)'s top line continues to grow despite its operational challenges, as second-quarter revenue jumped 56% year over year to about $405 million and 44% sequentially. The growth was helped by higher deliveries, a better product mix, a 3.7% increase in average selling price, and $25 million in additional regulatory credit sales. This growth gives Lucid a stronger revenue base as management works to improve the firm's basic economics.
New CEO Silvio Napoli has also introduced a specific turnaround plan with measurable targets. His operational reset plans to generate $1.4 billion in cash-flow improvements this year. It directly addresses problems such as premature product launches, inadequate service investment, and slow responses to quality issues. A more disciplined approach could help Lucid reduce execution problems and rebuild investor confidence.
#lucid #recall #problems #group
5 days ago
CNBC reported that Chris Churchman, The Goldman Sachs Group, Inc. (NYSE:GS) partner who leads the bank's Marquee digital platform for institutional clients, warned that AI's spread across Wall Street risks eroding the reasoning skills of the next generation of bankers.
Churchman said on Goldman's internal "Exchanges" podcast, "There's a huge danger here that in the era of AI, we outsource our reasoning to these models, and we have cognitive atrophy that stops us being able to reason from first principles ourselves." He compared it to how GPS and search engines eroded navigation skills and said much of banking's knowledge is learned only "by doing." Churchman said the firm has not yet determined how it will manage the transition.
The Goldman Sachs Group, Inc. (NYSE:GS) is surfacing this risk proactively, through its own senior AI leadership, rather than being caught off guard by it later. Having the executive who leads Marquee flag the danger publicly signals internal scrutiny that could help Goldman build safeguards into its AI rollout before problems show up in deal execution. It is an advantage over firms deploying AI without asking the same questions.
The near-term efficiency case for AI remains fully intact regardless of the long-term talent question. CNBC itself framed the tradeoff as a "devil's bargain" that could make the industry more profitable today while potentially eroding the talent it needs for tomorrow. It means Goldman still captures AI's productivity benefits now even as it works out the downstream risk.
Marquee itself is a genuine strategic **** et getting AI investment. The platform, through which hedge funds and other large institutional clients access Goldman's market data, research, **** ytics, and execution tools, is being built out with AI features, which positions it as a differentiated offering for Goldman's most valuable client relationships.
#churchman #marquee #cnbc #sachs
Churchman said on Goldman's internal "Exchanges" podcast, "There's a huge danger here that in the era of AI, we outsource our reasoning to these models, and we have cognitive atrophy that stops us being able to reason from first principles ourselves." He compared it to how GPS and search engines eroded navigation skills and said much of banking's knowledge is learned only "by doing." Churchman said the firm has not yet determined how it will manage the transition.
The Goldman Sachs Group, Inc. (NYSE:GS) is surfacing this risk proactively, through its own senior AI leadership, rather than being caught off guard by it later. Having the executive who leads Marquee flag the danger publicly signals internal scrutiny that could help Goldman build safeguards into its AI rollout before problems show up in deal execution. It is an advantage over firms deploying AI without asking the same questions.
The near-term efficiency case for AI remains fully intact regardless of the long-term talent question. CNBC itself framed the tradeoff as a "devil's bargain" that could make the industry more profitable today while potentially eroding the talent it needs for tomorrow. It means Goldman still captures AI's productivity benefits now even as it works out the downstream risk.
Marquee itself is a genuine strategic **** et getting AI investment. The platform, through which hedge funds and other large institutional clients access Goldman's market data, research, **** ytics, and execution tools, is being built out with AI features, which positions it as a differentiated offering for Goldman's most valuable client relationships.
#churchman #marquee #cnbc #sachs
5 days ago
Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a "years-long effort to strengthen its higher-growth businesses."
McKesson has been reshaping its portfolio by exiting non-core **** ets and streamlining its operations while investing in businesses such as oncology and specialty care. Precision Medicine Group, based in Bethesda, Maryland, provides clinical research, laboratory testing, and commercialization services that help biopharma companies develop and launch new medicines. It will become part of McKesson's Oncology & Multispecialty segment once the deal closes, though McKesson gave no completion timeline. CEO Brian Tyler said the acquisition would "enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."
The deal fits neatly into a growth strategy McKesson Corporation (NYSE:MCK) has already been executing, not a scattershot bet. The company has spent recent years exiting non-core **** ets while specifically building out oncology and specialty care. It means this acquisition extends a strategy management has already proven willing to follow through on.
McKesson is adding Precision Medicine to its strongest-performing division rather than using the acquisition to revive a struggling business. Revenue in the Oncology & Multispecialty segment jumped 33% to $14.2 billion in the first quarter of fiscal 2026, while JP Morgan **** yst Lisa Gill said the acquisition will likely strengthen McKesson's biopharma offerings.
The purchase reflects disciplined capital recycling, not new debt-fueled expansion. McKesson said in April it would sell a minority stake in its medical-surgical solutions business to Apollo Funds for $1.25 billion while pursuing an IPO for that unit, showing the company is actively shedding slower-growth **** ets to help fund investments like this one.
#medicine #acquisition #deal
McKesson has been reshaping its portfolio by exiting non-core **** ets and streamlining its operations while investing in businesses such as oncology and specialty care. Precision Medicine Group, based in Bethesda, Maryland, provides clinical research, laboratory testing, and commercialization services that help biopharma companies develop and launch new medicines. It will become part of McKesson's Oncology & Multispecialty segment once the deal closes, though McKesson gave no completion timeline. CEO Brian Tyler said the acquisition would "enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."
The deal fits neatly into a growth strategy McKesson Corporation (NYSE:MCK) has already been executing, not a scattershot bet. The company has spent recent years exiting non-core **** ets while specifically building out oncology and specialty care. It means this acquisition extends a strategy management has already proven willing to follow through on.
McKesson is adding Precision Medicine to its strongest-performing division rather than using the acquisition to revive a struggling business. Revenue in the Oncology & Multispecialty segment jumped 33% to $14.2 billion in the first quarter of fiscal 2026, while JP Morgan **** yst Lisa Gill said the acquisition will likely strengthen McKesson's biopharma offerings.
The purchase reflects disciplined capital recycling, not new debt-fueled expansion. McKesson said in April it would sell a minority stake in its medical-surgical solutions business to Apollo Funds for $1.25 billion while pursuing an IPO for that unit, showing the company is actively shedding slower-growth **** ets to help fund investments like this one.
#medicine #acquisition #deal
5 days ago
CNBC reported that NVIDIA Corporation (NASDAQ:NVDA)'s Groq 3 LPX rack is in full production and will be deployed alongside its Vera CPUs and Rubin GPUs at neocloud Nebius later this year, Nvidia senior director Dion Harris told reporters.
The rack marks the commercialization of technology from Nvidia's $20 billion purchase of Groq's ***** ets in December, its largest deal on record. Each liquid-cooled rack packages 256 Groq chips. Nvidia said the rack can deliver 3,400 tokens per second, noting a benchmark from Artificial ***** ysis. Groq's chips are manufactured by Samsung, unlike Nvidia's own GPUs, which are made by Taiwan Semiconductor Manufacturing Co.
The $20 billion Groq deal represents a manageable financial risk for NVIDIA Corporation (NASDAQ:NVDA) relative to the strategic capabilities it could add to the company. Bernstein ***** yst Stacy Rasgon told CNBC that Nvidia is financially strong enough to absorb a deal of this size with little impact on its overall position. That gives Nvidia the flexibility to make large strategic investments while expanding into new AI chip technologies without materially straining its balance sheet.
Groq's technology extends Nvidia's dominance across the full AI compute stack rather than creating a rival product line. LPX handles low-latency inference while Nvidia's GPUs continue handling training and large-context processing. The rack can pair with Vera Rubin chips without customers changing their CUDA workflows, deepening the software lock-in that has made Nvidia hard to displace.
Execution has been fast, which matters in a market moving this quickly. Nvidia went from announcing the Groq purchase in December to full production and a named customer, Nebius, in eight months. It is a pace that shows Nvidia can absorb acquired technology and ship it rather than let it stall in integration.
#rack
The rack marks the commercialization of technology from Nvidia's $20 billion purchase of Groq's ***** ets in December, its largest deal on record. Each liquid-cooled rack packages 256 Groq chips. Nvidia said the rack can deliver 3,400 tokens per second, noting a benchmark from Artificial ***** ysis. Groq's chips are manufactured by Samsung, unlike Nvidia's own GPUs, which are made by Taiwan Semiconductor Manufacturing Co.
The $20 billion Groq deal represents a manageable financial risk for NVIDIA Corporation (NASDAQ:NVDA) relative to the strategic capabilities it could add to the company. Bernstein ***** yst Stacy Rasgon told CNBC that Nvidia is financially strong enough to absorb a deal of this size with little impact on its overall position. That gives Nvidia the flexibility to make large strategic investments while expanding into new AI chip technologies without materially straining its balance sheet.
Groq's technology extends Nvidia's dominance across the full AI compute stack rather than creating a rival product line. LPX handles low-latency inference while Nvidia's GPUs continue handling training and large-context processing. The rack can pair with Vera Rubin chips without customers changing their CUDA workflows, deepening the software lock-in that has made Nvidia hard to displace.
Execution has been fast, which matters in a market moving this quickly. Nvidia went from announcing the Groq purchase in December to full production and a named customer, Nebius, in eight months. It is a pace that shows Nvidia can absorb acquired technology and ship it rather than let it stall in integration.
#rack
5 days ago
On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the pharmacy counter: ICOTYDE, an oral psoriasis treatment, and rusfertide, an injectable now awaiting an FDA decision. Cash and marketable securities climbed to $849.5 million. Here's what's fueling the optimism, and what could complicate it.
The quarter marked the first full three months of commercial sales for ICOTYDE, which won FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg. That approval triggered a $50 million milestone payment and made ICOTYDE, according to the company, the first and only FDA-approved targeted oral peptide for the condition. Protagonist can still collect up to $580 million more in milestones from partner Johnson & Johnson, plus royalties that average around 7.25 percent at $4 billion in annual sales.
Rusfertide carries even more weight. Its new drug application sits under Priority Review with a PDUFA goal date in August, backed by Breakthrough Therapy, Orphan Drug, and Fast Track designations for polycythemia vera. Partner Takeda already paid Protagonist $200 million on an opt-out election in April, with another $200 million and a $75 million approval milestone still due, on top of royalties that can reach 29 percent of sales above $1.5 billion. Behind both drugs, PN-881, an oral IL-17 antagonist, is heading into a Phase 2b psoriasis program in early 2027 after Phase 1 data showed drug levels beating their pharmacokinetic targets, and a Phase 1 study just began for PN-477sc, an injectable obesity peptide.
Look closer at that $213.5 million in license and collaboration revenue, and $192.4 million of it traces to the proportional recognition of Takeda's initial opt-out payment, not repeatable product sales. A year earlier, the same line item was just $5.5 million, so the growth reflects a single deal event more than an operating business scaling up. And that opt-out itself cuts both ways: Protagonist gave up its right to develop and commercialize rusfertide on its own, trading full ownership for royalties and milestones that depend on Takeda's execution rather than Protagonist's.
Spending is also set to climb. Management expects research and development costs to increase significantly in the second half of 2026 versus the first half, driven by the new PN-881 Phase 2b program, manufacturing investments, and added headcount. General and administrative costs are rising too, largely on stock-based compensation. And rusfertide's fate still hinges on an FDA decision that hasn't happened yet, priority review or not.
#protagonist
The quarter marked the first full three months of commercial sales for ICOTYDE, which won FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg. That approval triggered a $50 million milestone payment and made ICOTYDE, according to the company, the first and only FDA-approved targeted oral peptide for the condition. Protagonist can still collect up to $580 million more in milestones from partner Johnson & Johnson, plus royalties that average around 7.25 percent at $4 billion in annual sales.
Rusfertide carries even more weight. Its new drug application sits under Priority Review with a PDUFA goal date in August, backed by Breakthrough Therapy, Orphan Drug, and Fast Track designations for polycythemia vera. Partner Takeda already paid Protagonist $200 million on an opt-out election in April, with another $200 million and a $75 million approval milestone still due, on top of royalties that can reach 29 percent of sales above $1.5 billion. Behind both drugs, PN-881, an oral IL-17 antagonist, is heading into a Phase 2b psoriasis program in early 2027 after Phase 1 data showed drug levels beating their pharmacokinetic targets, and a Phase 1 study just began for PN-477sc, an injectable obesity peptide.
Look closer at that $213.5 million in license and collaboration revenue, and $192.4 million of it traces to the proportional recognition of Takeda's initial opt-out payment, not repeatable product sales. A year earlier, the same line item was just $5.5 million, so the growth reflects a single deal event more than an operating business scaling up. And that opt-out itself cuts both ways: Protagonist gave up its right to develop and commercialize rusfertide on its own, trading full ownership for royalties and milestones that depend on Takeda's execution rather than Protagonist's.
Spending is also set to climb. Management expects research and development costs to increase significantly in the second half of 2026 versus the first half, driven by the new PN-881 Phase 2b program, manufacturing investments, and added headcount. General and administrative costs are rising too, largely on stock-based compensation. And rusfertide's fate still hinges on an FDA decision that hasn't happened yet, priority review or not.
#protagonist
6 days ago
NRG Energy gained 6.4% and Constellation Energy rose 4.9% on September 4 while the S&P 500 fell 0.4%. The gains were consistent with the broader AI-power trade where data-center projects increasingly depend on generators that can add reliable capacity, navigate interconnection queues, and sign contracts before construction. NRG Energy, Inc. (NYSE:NRG) and Constellation Energy Corporation (NASDAQ:CEG) offer different versions of that opportunity.
NRG is advancing a Bring Your Own Power strategy with a hyperscaler for a 1.2-gigawatt combined-cycle gas project in Texas. It also brought a 415-megawatt facility into commercial operation and reported $1.03 billion of second-quarter free cash flow before growth investments. The bull case is speed: pairing contracted data-center load with dispatchable generation can bypass part of the grid bottleneck. The bear case is project execution, fuel exposure, financing, and the possibility that forecast load never materializes.
Insider Monkey counted 59 hedge funds holding NRG Energy, Inc. (NYSE:NRG) at June 30, down from 76 at March 31. Israel Englander's Millennium Management nevertheless disclosed 4,257,712 shares, 115% more than in Q1. The contrast between a falling fund count and one manager's larger position argues against treating institutional sentiment as uniform.
Constellation brings the largest U.S. nuclear fleet plus gas **** ets acquired with Calpine. It raised full-year adjusted operating EPS guidance to $11.50 to $12.50 and said it had signed another 920 megawatts of long-term power agreements. The bull case is scarce around-the-clock clean generation. The bear case includes plant outages, regulatory intervention, integration risk, and the danger of overpaying to expand capacity during a demand boom.
Seventy-three hedge funds held Constellation Energy Corporation (NASDAQ:CEG) in Q2, down from 79 in Q1. Philippe Laffont's Coatue Management disclosed 4,632,475 shares at quarter-end; the available profile did not show a usable sequential activity figure, so no motive or timing is inferred.
#energy #management
NRG is advancing a Bring Your Own Power strategy with a hyperscaler for a 1.2-gigawatt combined-cycle gas project in Texas. It also brought a 415-megawatt facility into commercial operation and reported $1.03 billion of second-quarter free cash flow before growth investments. The bull case is speed: pairing contracted data-center load with dispatchable generation can bypass part of the grid bottleneck. The bear case is project execution, fuel exposure, financing, and the possibility that forecast load never materializes.
Insider Monkey counted 59 hedge funds holding NRG Energy, Inc. (NYSE:NRG) at June 30, down from 76 at March 31. Israel Englander's Millennium Management nevertheless disclosed 4,257,712 shares, 115% more than in Q1. The contrast between a falling fund count and one manager's larger position argues against treating institutional sentiment as uniform.
Constellation brings the largest U.S. nuclear fleet plus gas **** ets acquired with Calpine. It raised full-year adjusted operating EPS guidance to $11.50 to $12.50 and said it had signed another 920 megawatts of long-term power agreements. The bull case is scarce around-the-clock clean generation. The bear case includes plant outages, regulatory intervention, integration risk, and the danger of overpaying to expand capacity during a demand boom.
Seventy-three hedge funds held Constellation Energy Corporation (NASDAQ:CEG) in Q2, down from 79 in Q1. Philippe Laffont's Coatue Management disclosed 4,632,475 shares at quarter-end; the available profile did not show a usable sequential activity figure, so no motive or timing is inferred.
#energy #management
6 days ago
AMD gained 4.7% and Intel rose 4.5% on September 4, while Nvidia added only 0.8%. The one-session gap is consistent with investors widening the AI trade beyond Nvidia, but it cannot identify buyer motive or prove a lasting rotation. Advanced Micro Devices, Inc. (NASDAQ:AMD) and Intel Corporation (NASDAQ:INTC) each offer a route to AI spending that does not require Nvidia to lose outright.
AMD's second-quarter revenue reached a record $11.5 billion, up 50% year over year, and Data Center represented 58% of the company. Its portfolio includes MI450 accelerators, sixth-generation EPYC processors, Helios rack-scale systems, and Pensando networking. Customers seeking a credible second source and more negotiating leverage support the bull case. The countercase is software maturity, execution across a broad roadmap, and the capital required to challenge Nvidia's ecosystem.
Insider Monkey's database counted 164 hedge funds holding Advanced Micro Devices, Inc. (NASDAQ:AMD) in Q2 2026, up from 134 in Q1 2026. Marshall Wace reported 3,898,210 shares, about 3% more than in Q1. The quarter-end filings predate the September 4 rally and cannot show whether funds reacted to it.
Intel's second-quarter Data Center and AI revenue was $6.3 billion, up 59% year over year. A resilient CPU franchise, custom silicon, advanced packaging, and a domestic foundry network form the bull case. The cost and uncertain returns of rebuilding manufacturing leadership form the bear case. Intel generated $1.8 billion of GAAP operating income, while its $2.16 GAAP loss per share was driven largely by a $12.5 billion noncash mark-to-market loss on escrowed shares. Negative $8.4 billion adjusted free cash flow still makes capital efficiency a real concern.
The Q2 2026 database counted 138 hedge funds holding Intel Corporation (NASDAQ:INTC), up from 112 in Q1 2026. AQR Capital Management reported 10,742,567 shares after cutting its position by about 6% from Q1. That disclosure also predates the September rally, so it is historical positioning rather than a reaction.
#billion #advanced #quarter
AMD's second-quarter revenue reached a record $11.5 billion, up 50% year over year, and Data Center represented 58% of the company. Its portfolio includes MI450 accelerators, sixth-generation EPYC processors, Helios rack-scale systems, and Pensando networking. Customers seeking a credible second source and more negotiating leverage support the bull case. The countercase is software maturity, execution across a broad roadmap, and the capital required to challenge Nvidia's ecosystem.
Insider Monkey's database counted 164 hedge funds holding Advanced Micro Devices, Inc. (NASDAQ:AMD) in Q2 2026, up from 134 in Q1 2026. Marshall Wace reported 3,898,210 shares, about 3% more than in Q1. The quarter-end filings predate the September 4 rally and cannot show whether funds reacted to it.
Intel's second-quarter Data Center and AI revenue was $6.3 billion, up 59% year over year. A resilient CPU franchise, custom silicon, advanced packaging, and a domestic foundry network form the bull case. The cost and uncertain returns of rebuilding manufacturing leadership form the bear case. Intel generated $1.8 billion of GAAP operating income, while its $2.16 GAAP loss per share was driven largely by a $12.5 billion noncash mark-to-market loss on escrowed shares. Negative $8.4 billion adjusted free cash flow still makes capital efficiency a real concern.
The Q2 2026 database counted 138 hedge funds holding Intel Corporation (NASDAQ:INTC), up from 112 in Q1 2026. AQR Capital Management reported 10,742,567 shares after cutting its position by about 6% from Q1. That disclosure also predates the September rally, so it is historical positioning rather than a reaction.
#billion #advanced #quarter
